PHAXIAM Therapeutics SA (PHXM) Stock

Profile

Full Name:

PHAXIAM Therapeutics S.A.

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

26 October 2017

Indexes:

Not included

Website:

http://www.phaxiam.com

Description:

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$0.11(+99.61% YoY)

PE Ratio

-

Annual ROE

-0.95%

Annual Debt To Equity

0.58

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Mar 22, 2024

Recent annual earnings:

Mar 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sept 20, 2023

Analyst ratings

Recent major analysts updates

05 Dec '17 Cowen & Co.
Outperform

Screeners with PHXM included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$303.00
PHXM price is currently at an all-time high

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Net Income 3-Year Change

+99.66%
PHXM annual net profit is up +99.66% over the past 3 years

Annual EPS 3-Year Change

+99.73%
PHXM annual earnings per share is up +99.73% over the past 3 years

Annual Operating Profit

-$28.63 M
PHXM annual operaing income is -$28.63 million

Annual Operating Profit 3-Year Change

+60.09%
PHXM annual operaing income is up +60.09% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-0.95%
PHXM annual return on equity is -0.95%

Annual ROA

-0.49%
PHXM annual return on assets is -0.49%

Annual EBIT

$645.40 K
PHXM annual earnings before interest & taxes is $645.40 thousand

Annual EBITDA

$3.71 M
PHXM annual earnings before interest, taxes, depreciation & amortization is $3.71 million

Annual Interest Coverage Ratio

1.92
PHXM annual interest coverage ratio is 1.92

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Quick Ratio

3.65
PHXM annual quick ratio is 3.65

Annual Current Ratio

3.65
PHXM annual current ratio is 3.65

Annual Total Assets

$49.13 M
PHXM annual total assets is $49.13 million

Annual Current Assets

$45.72 M
PHXM annual total current assets is $45.72 million

Annual Total Liabilities

$23.94 M
PHXM annual total liabilities is $23.94 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+30.91%
PHXM annual cash flow from operations is up +30.91% over the past 3 years

Annual CFI 3-Year Change

+281.05%
PHXM annual cash flow from investing activities is up +281.05% over the past 3 years

Annual CFF 3-Year Change

-4261.83%
PHXM annual cash flow from financing activities is down -4261.83% over the past 3 years

Annual FCF

-$33.59 M
PHXM annual free cash flow is -$33.59 million

Annual FCF 3-Year Change

+52.71%
PHXM annual free cash flow is up +52.71% over the past 3 years

Institutional Ownership

Similar stocks

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
PHXM
globenewswire.com27 November 2024

Lyon (France) – November 27, 2024, at 02:30 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, presented an ambitious development strategy to take advantage of the rapidly evolving phage therapy area.

PHAXIAM Reports Third-Quarter 2024 Financial Information
PHAXIAM Reports Third-Quarter 2024 Financial Information
PHAXIAM Reports Third-Quarter 2024 Financial Information
PHXM
globenewswire.com13 November 2024

Lyon (France), November 13, 2024, at 5:45 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today reports its financial results for the third quarter of 2024.

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
PHXM
globenewswire.com04 November 2024

Lyon (France), November 04, 2024 – 6:00 pm CET - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announces that it has received Investigational New Drug approval (IND) for its Phase II study, GLORIA, in Prosthetic Joint Infections (PJI) caused by Staphylococcus aureus (S. aureus).

PHAXIAM Provides Business and Financial Update For the First Half of 2024
PHAXIAM Provides Business and Financial Update For the First Half of 2024
PHAXIAM Provides Business and Financial Update For the First Half of 2024
PHXM
globenewswire.com25 September 2024

Lyon (France), September 25, 2024 at 5:45 pm CEST – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today provides a business and financial update for the first half of 2024.

PHAXIAM Therapeutics S.A. (PHXM) Q3 2023 Earnings Call Transcript
PHAXIAM Therapeutics S.A. (PHXM) Q3 2023 Earnings Call Transcript
PHAXIAM Therapeutics S.A. (PHXM) Q3 2023 Earnings Call Transcript
PHXM
Seeking Alpha17 November 2023

PHAXIAM Therapeutics S.A. (NASDAQ:PHXM ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Thibaut Fayet - CEO Pascal Birman - CMO Eric Soyer - CFO Conference Call Participants Operator Good day, and welcome to the PHAXIAM Therapeutics Business Update and Financial Highlights of Q3 2023.

FAQ

  • What is the primary business of PHAXIAM Therapeutics SA?
  • What is the ticker symbol for PHAXIAM Therapeutics SA?
  • Does PHAXIAM Therapeutics SA pay dividends?
  • What sector is PHAXIAM Therapeutics SA in?
  • What industry is PHAXIAM Therapeutics SA in?
  • What country is PHAXIAM Therapeutics SA based in?
  • When did PHAXIAM Therapeutics SA go public?
  • Is PHAXIAM Therapeutics SA in the S&P 500?
  • Is PHAXIAM Therapeutics SA in the NASDAQ 100?
  • Is PHAXIAM Therapeutics SA in the Dow Jones?
  • When was PHAXIAM Therapeutics SA's last earnings report?
  • When does PHAXIAM Therapeutics SA report earnings?

What is the primary business of PHAXIAM Therapeutics SA?

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

What is the ticker symbol for PHAXIAM Therapeutics SA?

The ticker symbol for PHAXIAM Therapeutics SA is NASDAQ:PHXM

Does PHAXIAM Therapeutics SA pay dividends?

No, PHAXIAM Therapeutics SA does not pay dividends

What sector is PHAXIAM Therapeutics SA in?

PHAXIAM Therapeutics SA is in the Healthcare sector

What industry is PHAXIAM Therapeutics SA in?

PHAXIAM Therapeutics SA is in the Biotechnology industry

What country is PHAXIAM Therapeutics SA based in?

PHAXIAM Therapeutics SA is headquartered in France

When did PHAXIAM Therapeutics SA go public?

PHAXIAM Therapeutics SA's initial public offering (IPO) was on 26 October 2017

Is PHAXIAM Therapeutics SA in the S&P 500?

No, PHAXIAM Therapeutics SA is not included in the S&P 500 index

Is PHAXIAM Therapeutics SA in the NASDAQ 100?

No, PHAXIAM Therapeutics SA is not included in the NASDAQ 100 index

Is PHAXIAM Therapeutics SA in the Dow Jones?

No, PHAXIAM Therapeutics SA is not included in the Dow Jones index

When was PHAXIAM Therapeutics SA's last earnings report?

PHAXIAM Therapeutics SA's most recent earnings report was on 22 March 2024

When does PHAXIAM Therapeutics SA report earnings?

The date for PHAXIAM Therapeutics SA's next earnings report has not been announced yet